HER2-positive Metastatic Breast Cancer
29
11
17
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
10.3%
3 terminated out of 29 trials
50.0%
-36.5% vs benchmark
7%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (29)
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Testing a New Imaging Agent to Identify Cancer
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
PRE-I-SPY Phase I/Ib Oncology Platform Program
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ARX788 in HER2-positive Metastatic Breast Cancer Patients
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer